Alzecure Announces Positive Outcomes From Phase I Clinical Trial of NeuroRestore ACD856 for Alzheimer's Disease
Thursday, August 10, 2023
AlzeCure Pharma AB (publ) (FN STO: ALZCUR) is a pharmaceutical company dedicated to the development of small molecule candidate drugs targeting disorders of the central nervous system. The company's research efforts span projects addressing Alzheimer's disease and pain management.
Recently, AlzeCure Pharma announced the publication of a significant scientific article detailing their lead candidate drug, NeuroRestore ACD856. The publication titled "Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects," appeared in The Journal of Prevention of Alzheimer's Disease. Dr. Märta Segerdahl, Chief Medical Officer at AlzeCure Pharma, is the corresponding author of the article, and collaborators on the work include Kristin Önnestam, Boel Nilsson, Matthias Rother, Erik Rein-Hedin, Johan Bylund, Peter Anderer, Manuel Kemethofer, Magnus Halldin, and Johan Sandin.
The focus of the published article lies in the results of the clinical phase I study, particularly the segment known as the Multiple Ascending Dose (MAD) phase. The outcomes detailed in the article underscore the favorable safety and tolerability profile of ACD856, the lead candidate drug within the NeuroRestore platform. Furthermore, the substance exhibits desirable pharmacokinetic characteristics, including rapid absorption in the body and dose-dependent exposure within the central nervous system. Notably, ACD856 has shown the ability to enhance EEG (electroencephalography) activity in the brain, indicating its potential to engage key brain regions associated with cognitive improvement and antidepressant effects.
Dr. Märta Segerdahl, CMO of AlzeCure Pharma, expressed enthusiasm for the promising results presented in the article. She emphasized ACD856's potential for further clinical advancement, particularly its promising impact on memory functions in various diseases. Its potential in addressing conditions like Alzheimer's disease, traumatic brain injury, and Parkinson's disease is particularly noteworthy.
ACD856 operates as a Trk-PAM (Positive Allosteric Modulator) and facilitates the enhancement of signaling through BDNF (Brain-Derived Neurotrophic Factor) and NGF (Nerve Growth Factor), both pivotal for normal neuronal function. The drug is being developed to alleviate symptoms in medical conditions leading to impaired cognitive abilities, such as Alzheimer's disease. Encouraging preclinical data also suggests potential protective and disease-modifying effects.
AlzeCure Pharma's CEO, Martin Jönsson, highlighted the promising clinical phase I data for ACD856. Given the substantial demand for innovative treatments in the Alzheimer's field, the positive results associated with ACD856's potential to enhance learning, memory, and depression-related therapies are especially encouraging. These findings are expected to stimulate discussions about partnerships and licensing agreements, further enhancing interest in the comprehensive NeuroRestore platform.
